aMoon 2 Fund Limited Partnership 4
4 · Ayala Pharmaceuticals, Inc. · Filed May 14, 2020
Insider Transaction Report
Form 4
aMoon 2 Fund Limited Partnership
10% Owner
Transactions
- Conversion
Common Stock
2020-05-12+369,231→ 1,682,549 total - Conversion
Common Stock
2020-05-12+508,924→ 2,191,473 total - Purchase
Common Stock
2020-05-12$15.00/sh+800,000$12,000,000→ 2,991,473 total - Conversion
Series A Preferred Stock
2020-05-12−738,462→ 0 total→ Common Stock (369,231 underlying) - Conversion
Series B Preferred Stock
2020-05-12−1,017,848→ 0 total→ Common Stock (508,924 underlying)
Footnotes (1)
- [F1]Each share of preferred stock was automatically converted into 0.5 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date.